Video | July 29, 2020

How Is The Overall Environment For Development Of Innovative Medicines And Biomedical Technologies?

Source: Life Science Leader

Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmaceutical companies (view full video here). In this segment, Rachel King, CEO of GlycoMimetics (NASDAQ: GLYC), and Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), discuss the current drug development environment during the pandemic.